A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

PHASE1,PHASE2

Phase

COMPLETED

Status

669

Enrollment

INDUSTRY

Sponsor class

Conditions

BIOLOGICAL: Placebo
BIOLOGICAL: RSV preF Protein 50 mcg
BIOLOGICAL: RSV preF Protein 150 mcg
BIOLOGICAL: Ad26.RSV.preF 1*10^11 vp
BIOLOGICAL: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg
BIOLOGICAL: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg
BIOLOGICAL: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg
BIOLOGICAL: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg
BIOLOGICAL: Selected Regimen

Janssen Vaccines & Prevention B.V.